Improved perception of IGLARLIXI therapy compared to mixed insulin when transferred from basal insulin: outcomes reported by patients in the SoliMix study

Abstract

Since type 2 diabetes mellitus (DM2) is characterized by a progressive loss of pancreatic beta cell function, there is a need to add insulin to current therapy in order to compensate for the disease and prevent the development of complications. The clinical recommendations suggest various options for the intensification of DM2 therapy: both monopreparations of insulin and its combination with aGPP-1. The latter have demonstrated clinical efficacy in achieving glycemic control and a favorable safety profile in clinical trials. Another important issue is the perception of treatment by the patient himself, since for many people, changing therapy or changing the “format” itself (prescribing injections) can be accompanied by additional stress.The purpose of this study was to study the efficacy and safety, as well as the perception of patients with treatment of DM2 when using a fixed combination of insulin glargine/lixisenatide (Iglarlixi) compared with mixed insulin – biphasic aspartame 30.